{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "No"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [
            "No"
      ],
      "ArmGroupDescription": [
            "Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.",
            "Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min."
      ],
      "ArmGroupInterventionName": [
            "Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Drug: Lactated Ringer's Solution"
      ],
      "ArmGroupLabel": [
            "Experimental: Human (aMBMC)",
            "Placebo:Lactated Ringer's Solution (LRS)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "Female",
            "Male",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported",
            "Class II",
            "Class III"
      ],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02467387"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [
            "BG000"
      ],
      "BaselineDenomCountValue": [
            "22"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "itMSC, then Placebo: Participants first received itMSC 1.5 million per kilogram of weight, infused in the corresponding hospital facility at speed of 1 mL/minute (cell concentration 1 million/mL). After 90 days patients completed treatment at 90 days, and thus constituted the control treatment. After 90 day follow-up testing patients received Placebo and followed up for another 90 days. Total efficacy follow-up - 180 days. Safety follow-up - 240 days.\n\nPlacebo, then itMSC: Participants first received Placebo, infused in the corresponding hospital facility at speed of 1 mL/minute. After 90 days patients completed Placebo Control and related testing, and received itMSC treatment 1.5 million per kilogram of weight, and thus constituted the itMSC treated group for another 90 days.Total efficacy follow-up - 180 days. Safety follow-up - 240 days. and thus constituted the control treatment."
      ],
      "BaselineGroupId": [
            "BG000"
      ],
      "BaselineGroupTitle": [
            "Study Population"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [
            "NYHA Class:\n\nClass I (Mild): Patients with cardiac disease but without resulting in limitation of physical activity.\n\nClass II (Mild): Cardiac disease resulting in slight limitation of physical activity.\n\nClass III (Moderate): Cardiac disease resulting in marked limitation of physical activity.\n\nClass IV (Severe): Cardiac disease resulting in the inability to carry on any physical activity without discomfort.\n\nImprovement in NYHA classification was analyzed using logistic regression with treatment and group assignment (itMSC - placebo vs. placebo - itMSC) as covariates."
      ],
      "BaselineMeasureDispersionType": [
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation"
      ],
      "BaselineMeasureParamType": [
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Mean",
            "Mean",
            "Count of Participants",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Mean",
            "Mean",
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants"
      ],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [
            "Age, Continuous",
            "Sex: Female, Male",
            "Race (NIH/OMB)",
            "Weight",
            "BMI",
            "New York Heart Association (NYHA) Class",
            "Systolic Blood Pressure",
            "Diastolic Blood Pressure",
            "Heart Rate",
            "N-terminlal-proB-type Natriuretic Peptide (NT-proBNP)",
            "Troponin I",
            "Serum Sodium",
            "Serum Creatinine",
            "Aspartate Aminotransferase (AST)",
            "Alanine Aminotransferase (ALT)",
            "Total bilirubin",
            "Albumin",
            "History of Hypertension",
            "History of Diabetes",
            "History of Atrial Fibrillation",
            "History of Kidney Disease",
            "Left Ventricular Ejection Fraction (LVEF)",
            "Left Ventricular End Systolic Volume (LVESV)",
            "Left Ventricular End-Diastolic Volume (LVEDV)",
            "Loop diuretic medication",
            "angiotensin converting enzyme inhibitors (ACEI) or Angiotensin II Receptor Blockers (ARB) medication",
            "Mineralocorticoid Receptor Antagonist medication",
            "Beta-blocker"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "years",
            "Participants",
            "Participants",
            "kg",
            "kg/m^2",
            "Participants",
            "mmHg",
            "mmHg",
            "bpm",
            "pg/mL",
            "ug/mL",
            "mmol/L",
            "mg/dL",
            "International Units/milliliter (IU/mL)",
            "IU/L",
            "mg/dL",
            "g/dL",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "%",
            "mL",
            "mL",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000"
      ],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [
            "12.8",
            "19.96",
            "7.56",
            "17.1",
            "9.6",
            "14.2",
            "841",
            "0.0003",
            "2",
            "0.23",
            "8.64",
            "9.57",
            "0.4",
            "0.36",
            "9.8",
            "114.2",
            "120.4"
      ],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [
            "47.3",
            "9",
            "13",
            "0",
            "0",
            "0",
            "7",
            "15",
            "0",
            "0",
            "92.5",
            "32.24",
            "21",
            "1",
            "120",
            "74",
            "78",
            "212",
            "0.0009",
            "138",
            "0.96",
            "21.86",
            "21.82",
            "0.8",
            "4.2",
            "5",
            "3",
            "2",
            "1",
            "31.6",
            "189.6",
            "264.9",
            "16",
            "22",
            "18",
            "22"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure."
      ],
      "BriefTitle": [
            "A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "Stemedica Cell Technologies, Inc."
      ],
      "CompletionDate": [
            "May 11, 2017"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Non-Ischemic Heart Failure"
      ],
      "ConditionAncestorId": [
            "D000006331",
            "D000002318"
      ],
      "ConditionAncestorTerm": [
            "Heart Diseases",
            "Cardiovascular Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC14",
            "All",
            "BC23"
      ],
      "ConditionBrowseBranchName": [
            "Heart and Blood Diseases",
            "All Conditions",
            "Symptoms and General Pathology"
      ],
      "ConditionBrowseLeafAsFound": [
            "Heart Failure"
      ],
      "ConditionBrowseLeafId": [
            "M8573",
            "M9695",
            "M8571"
      ],
      "ConditionBrowseLeafName": [
            "Heart Failure",
            "Ischemia",
            "Heart Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000006333"
      ],
      "ConditionMeshTerm": [
            "Heart Failure"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Crossover Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Single"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant"
      ],
      "DetailedDescription": [
            "A phase IIa, single-blind, placebo-controlled, crossover, multi-center, randomized study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of ischemia-tolerant allogeneic mesenchymal bone marrow cells to subjects with heart failure of non-ischemic etiology."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMales and females \u226518 years of age\nLVEF \u226435% on echocardiogram within 12 months of randomization to undergo MRI\n\nScreening cardiac MRI at baseline with:\n\nEjection fraction \u226440% No significant hyper enhancement on MRI scan in the opinion of the central imaging lab reviewer\n\nPatients with non-ischemic heart failure etiology, as documented by absent or non-obstructive coronary artery disease on x-ray angiography or coronary computed tomography\nPatients with history of heart failure and treated for at least three months with GDMT\nNYHA class II-III symptoms\nAbility to understand and provide signed informed consent\nReasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits\n\nExclusion Criteria:\n\nPregnant or nursing women or those of childbearing age and not using an effective method of contraception\nHistory of stroke within 3 months\nCardiac surgery within 3 months prior to randomization or the likelihood of a requirement for such procedures during the study period\nCurrent ICD or CRT or implantation planned within 6 months of infusion\nPresence of clinically significant, uncorrected valvular heart disease, hypertrophic or restrictive cardiomyopathy, active myocarditis, or uncontrolled hypertension\nHistory of cardiac arrest or life-threatening arrhythmias within 3 months\nTreatment with parenteral inotropic agents within 1 month of randomization\nAnticipated cardiac transplantation within 1 year\nIllness other than heart failure with life expectancy less than 1 year\nReceived an experimental drug or device within 30 days of randomization\nLeft ventricular assist device or implantation planned in the next 6 months\nPatients with complex congenital heart disease\nUncontrolled seizure disorder\nPresence of immune deficiency\n\nClinically significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests:\n\nLiver disease = ALT or AST > 3x normal, alkaline phosphatase or bilirubin >2x normal)\nRenal disease = estimated glomerular filtration rate as assessed by the MDRD formula <30 ml/min\nHematologic = Unexplained leukocytosis >10 or hemoglobin < 9gm/dl\nPresence of any other clinically-significant medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the investigator or sponsor for which participation in the study would pose a safety risk to the subject\nInability to comply with the conditions of the protocol\nMalignancy within the previous five years, except adequately treated basal cell carcinoma, provided that it is neither infiltrating nor sclerosing, and carcinoma in situ of the cervix\nActive myocarditis or early postpartum cardiomyopathy (within six months).\nSystemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment\nPorphyria\nAllergy to sodium citrate or any \"caine\" type of local anesthetic\nAny contraindication for gadolinium use for MRI\nPatient scheduled for hospice care\nClinically relevant abnormal findings in the clinical history, physical examination, ECG, or laboratory tests at the screening assessment that would interfere with the objectives of the study or would preclude safe completion of the study. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as patients undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury\nAny other medical, social, or geographical factor that would make it unlikely that the patient could comply with study procedures (e.g., alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or noncompliance)"
      ],
      "EnrollmentCount": [
            "23"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "0",
            "0"
      ],
      "EventGroupDeathsNumAtRisk": [
            "22",
            "20"
      ],
      "EventGroupDescription": [
            "Subjects that received experimental drug, 22 subjects",
            "Subjects that received placebo, 20 subjects"
      ],
      "EventGroupId": [
            "EG000",
            "EG001"
      ],
      "EventGroupOtherNumAffected": [
            "18",
            "15"
      ],
      "EventGroupOtherNumAtRisk": [
            "22",
            "20"
      ],
      "EventGroupSeriousNumAffected": [
            "1",
            "1"
      ],
      "EventGroupSeriousNumAtRisk": [
            "22",
            "20"
      ],
      "EventGroupTitle": [
            "Experimental",
            "Placebo"
      ],
      "EventsDescription": [
            "All AE summaries were restricted to treatment-emergent adverse events (TEAEs), and TEAEs were defined as those AEs with onset after the first dose of study treatment or existing events that worsened after the first dose during the study.\n\nTreatment-emergent AEs by severity (severe, other), relationship to study treatment (\"related\" or \"not related\"). Reported treshold 5%."
      ],
      "EventsFrequencyThreshold": [
            "5"
      ],
      "EventsTimeFrame": [
            "450 days"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowAchievementNumSubjects": [
            "11",
            "12",
            "10",
            "12",
            "10",
            "12",
            "1",
            "0",
            "10",
            "12",
            "7",
            "12",
            "3",
            "0"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [
            "Participants first received itMSC 1.5 million per kilogram of weight, infused in the corresponding hospital facility at speed of 1 mL/minute (cell concentration 1 million/mL). After 90 days patients completed treatment at 90 days, and thus constituted the control treatment. After 90 day follow-up testing patients received Placebo and followed up for another 90 days. Total efficacy follow-up - 180 days. Safety measurements 0, 60, 90, days 270 and 450.",
            "Participants first received Placebo, infused in the corresponding hospital facility at speed of 1 mL/minute. After 90 days patients completed Placebo Control and related testing, and received itMSC treatment 1.5 million per kilogram of weight, and thus constituted the itMSC treated group for another 90 days.Total efficacy follow-up - 180 days. Safety measurements 0, 60, 90, days 270 and 450."
      ],
      "FlowGroupId": [
            "FG000",
            "FG001"
      ],
      "FlowGroupTitle": [
            "itMSC, Then Placebo",
            "Placebo, Then itMSC"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "Received Treatment as Randomized",
            "COMPLETED",
            "NOT COMPLETED",
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "First Intervention",
            "Second Intervention"
      ],
      "FlowPreAssignmentDetails": [
            "23 out of 34 patients have been randomized and 22 received the study intervention. Of those not randomized, 10 did not meet inclusion criteria and 1 could not tolerate CMR."
      ],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [
            "34 patients have been screened for eligibility between June, 2014 and April, 2016 at Emory University Medical Center, Atlanta, GA, Northwestern University Medical Center, Chicago, IL, University of Pennsylvania Medical Center, Philadelphia, PA, and Stony Brook University Medical Center, Stony Brook, NY."
      ],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Experimental: Human (aMBMC)",
            "Placebo:Lactated Ringer's Solution (LRS)"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M21013"
      ],
      "InterventionBrowseLeafName": [
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.",
            "One time infusion 1.5mL/kg"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
            "Lactated Ringer's Solution"
      ],
      "InterventionOtherName": [
            "Mesenchymal Stem Cells, (MSC) Marrow Stromal Cells.",
            "(LRS)"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Non-ischemic Heart Failure",
            "Stem Cells"
      ],
      "LargeDocDate": [
            "February 19, 2014"
      ],
      "LargeDocFilename": [
            "Prot_SAP_000.pdf"
      ],
      "LargeDocHasICF": [
            "No"
      ],
      "LargeDocHasProtocol": [
            "Yes"
      ],
      "LargeDocHasSAP": [
            "Yes"
      ],
      "LargeDocLabel": [
            "Study Protocol and Statistical Analysis Plan"
      ],
      "LargeDocTypeAbbrev": [
            "Prot_SAP"
      ],
      "LargeDocUploadDate": [
            "11/14/2019 16:47"
      ],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 7, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 6, 2020"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "CardioCell LLC"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Washington",
            "Atlanta",
            "Chicago",
            "Stony Brook",
            "Philadelphia"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "MedStar Washington Hospital Center",
            "Emory University Hospital",
            "Northwestern University Centers for Heart Failure Therapy",
            "Stony Brook Heart Institute",
            "Hospital of the University of Pennsylvania, Heart Failure and Transplant Program"
      ],
      "LocationState": [
            "District of Columbia",
            "Georgia",
            "Illinois",
            "New York",
            "Pennsylvania"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "20010",
            "30322",
            "60611",
            "11794",
            "19104"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [
            "NCT02123706"
      ],
      "OfficialTitle": [
            "A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "CardioCell LLC"
      ],
      "OrgStudyId": [
            "STEM-104-M-CHF"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [
            "General disorders",
            "Investigations",
            "Infections and infestations",
            "Metabolism and nutrition disorders",
            "Nervous system disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Musculoskeletal and connective tissue disorders"
      ],
      "OtherEventSourceVocabulary": [
            "MedDRA (17.0)",
            "MedDRA (17.0)",
            "MedDRA (17.0)",
            "MedDRA (17.0)",
            "MedDRA (17.0)",
            "MedDRA (17.0)",
            "MedDRA (17.0)"
      ],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "OtherEventStatsNumAffected": [
            "3",
            "11",
            "6",
            "4",
            "3",
            "9",
            "8",
            "4",
            "10",
            "0",
            "2",
            "6",
            "6",
            "1"
      ],
      "OtherEventStatsNumAtRisk": [
            "22",
            "20",
            "22",
            "20",
            "22",
            "20",
            "22",
            "20",
            "22",
            "20",
            "22",
            "20",
            "22",
            "20"
      ],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [
            "General Disorders and administration site condition: chest pain, fatigue, pyrexia",
            "Venous Pressure Jugular Increased",
            "Upper Respiratory Tract, Nasopharyngitis",
            "Fluid Overload, Dehydration",
            "Dizziness, headache",
            "Oropharyngeal Pain",
            "Muscle Spasms"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeClassDenomCountValue": [
            "12",
            "12",
            "9",
            "12"
      ],
      "OutcomeClassDenomUnits": [
            "Participants",
            "Participants"
      ],
      "OutcomeClassTitle": [
            "Adverse Events",
            "Serious Adverse Events",
            "Cell related adverse events",
            "All-cause hospitalization",
            "All-cause death",
            "Baseline (%)",
            "90 days (%)"
      ],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeDenomCountValue": [
            "22",
            "20",
            "12",
            "12"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "Participants received itMSC",
            "Participants received Placebo",
            "Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.\n\nAllogeneic Mesenchymal Bone Marrow Cells (itMSC): One time infusion Allogeneic Mesenchymal Bone Marrow Cells (itMSC) 1.5 million cells/kg.",
            "Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.\n\nLactated Ringer's Solution: One time infusion 1.5mL/kg"
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeGroupTitle": [
            "Experimental",
            "Placebo",
            "Experimental: Human (itMSC)",
            "Placebo:Lactated Ringer's Solution (LRS)"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "As identified in the SAP, the safety analysis was the primary objective and was evaluated by the number of AEs",
            "The secondary efficacy endpoint was the change in LVEF from baseline to Day 90 post-initial infusion. Participants with data available at each time point."
      ],
      "OutcomeMeasureDispersionType": [
            "Standard Deviation"
      ],
      "OutcomeMeasureParamType": [
            "Number",
            "Mean"
      ],
      "OutcomeMeasurePopulationDescription": [
            "All 22 participants that received itMSC treatment were included. All adverse events are divided into serious and non-serious.",
            "The secondary efficacy endpoint according to the protocol was the change in LVEF from baseline to Day 90 post-initial infusion."
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "Total AEs and SAEs within 450 days post-infusion",
            "Baseline to Day 90"
      ],
      "OutcomeMeasureTitle": [
            "Safety Will be Evaluated by Number of AE",
            "Change in LVEF From Baseline to Day 90 Post-initial Infusion."
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "number of events",
            "percentage of ejection volume"
      ],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [
            "7.91",
            "7.49",
            "9.7",
            "5.42"
      ],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [
            "38",
            "35",
            "1",
            "1",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "34.3",
            "34.5",
            "34.1",
            "36.7"
      ],
      "OverallOfficialAffiliation": [
            "Clinical Operations Manager"
      ],
      "OverallOfficialName": [
            "Kristrun Stardal, RN, BSN"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [
            "SSIKORA@STEMCARDIOCELL.COM"
      ],
      "PointOfContactOrganization": [
            "CardioCell, LLC"
      ],
      "PointOfContactPhone": [
            "760-315-0861"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Sergey Sikora, President and CEO"
      ],
      "PrimaryCompletionDate": [
            "May 11, 2017"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "As identified in the SAP, the safety analysis was the primary objective and was evaluated by the number of AEs"
      ],
      "PrimaryOutcomeMeasure": [
            "Safety Will be Evaluated by Number of AE"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Total AEs and SAEs within 450 days post-infusion"
      ],
      "ReferenceCitation": [
            "Butler J, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Ko YA, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. Circ Res. 2017 Jan 20;120(2):332-340. doi: 10.1161/CIRCRESAHA.116.309717. Epub 2016 Nov 16."
      ],
      "ReferencePMID": [
            "27856497"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [
            "January 7, 2020"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "October 25, 2019"
      ],
      "ResultsFirstSubmitQCDate": [
            "January 6, 2020"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "The secondary efficacy endpoint was the change in LVEF from baseline to Day 90 post-initial infusion. Participants with data available at each time point."
      ],
      "SecondaryOutcomeMeasure": [
            "Change in LVEF From Baseline to Day 90 Post-initial Infusion."
      ],
      "SecondaryOutcomeTimeFrame": [
            "Baseline to Day 90"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Systematic Assessment"
      ],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [
            "Cardiac disorders"
      ],
      "SeriousEventSourceVocabulary": [
            "MedDRA (17.0)"
      ],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001"
      ],
      "SeriousEventStatsNumAffected": [
            "1",
            "1"
      ],
      "SeriousEventStatsNumAtRisk": [
            "22",
            "20"
      ],
      "SeriousEventStatsNumEvents": [
            "1",
            "1"
      ],
      "SeriousEventTerm": [
            "atrial fibrillation"
      ],
      "StartDate": [
            "June 1, 2014"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "December 2019"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 10, 2015"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "June 2, 2015"
      ],
      "StudyFirstSubmitQCDate": [
            "June 9, 2015"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}